IgE antibody-specific abrogation of an established immune response in mice by modified antigens

DBA/1 mice were immunized with low doses of ovalbumin and alumina gel to elicit an IgE response which could be augmented upon reimmunization. Treatment of IgE-producing mice with high doses of chemically modified ovalbumin preparations markedly reduced or eliminated the ability of the mice to respond to subsequent reimmunizations with low doses of ovalbumin. It was found that the primary structural requirement for efficacy of the modified ovalbumins was reduced antigenicity to prevent the anaphylactic demise of the animals. Cumulative doses of 0.5 mg or more given in several increments, i.v., afforded optimal protection. The protection was antigen-specific and persisted for 2 to 3 months regardless of intervening exposures of the animals to low doses of antigen. It could be extended by further courses of treatment. There was no correlation between the levels of circulating hemagglutinating or total antibody and the induction of unresponsiveness. Nor was the passive administration of antibody able to approximate the effects of the modified antigens. It is suggested that the induction of the IgE class specific unresponsiveness in responding animals may take p;ace via effects on T cells.

Related Concept Videos

In-vitro Mutagenesis01:16

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Affinity and Avidity01:41

Affinity and Avidity

Overview
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Special Features of Adaptive Immunity01:20

Special Features of Adaptive Immunity

The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
Antibody Actions01:26

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...